Therapeutic use and function of recombinant molecules can be studied by the expression of foreign genes in mice. In this study, we have expressed human Fcg receptor --Ig fusion molecules (FcgR-Igs) in mice by administering FcgR-Ig plasmid DNAs hydrodynamically and compared their effectiveness with purified molecules in blocking immune-complex (IC)-mediated inflammation in mice. The concentration of hydrodynamically expressed FcgR-Igs (CD16A F -Ig, CD32A R -Ig and CD32A H -Ig) reached a maximum of 130 mg ml --1 of blood within 24 h after plasmid DNA administration. The in vivo half-life of FcgR-Igs was found to be 9 --16 days and western blot analysis showed that the FcgR-Igs were expressed as a homodimer. The hydrodynamically expressed FcgR-Igs blocked 50 --80% of IC-mediated inflammation up to 3 days in a reverse passive Arthus reaction model. Comparative analysis with purified molecules showed that hydrodynamically expressed FcgR-Igs are more efficient than purified molecules in blocking IC-mediated inflammation and had a higher half-life. In summary, these results suggest that the administration of a plasmid vector with the FcgR-Ig gene can be used to study the consequences of blocking IC binding to FcgRs during the development of inflammatory diseases. This approach may have potential therapeutic value in treating IC-mediated inflammatory autoimmune diseases such as lupus, arthritis and autoimmune vasculitis.
INTRODUCTION
The in vivo expression of a foreign gene in animal models is of great interest because it not only provides an opportunity to study the structure/function of a protein, but also has therapeutic efficacy in treating various pathological disorders. In vivo transgene expression requires efficient delivery of specific genes into the cells. Currently, viral and nonviral vectors are the two predominant gene delivery systems being used. Recently, it has been shown that a significant amount of protein can be expressed in vivo by rapidly injecting plasmid DNA in a large volume through the tail vein by a process called hydrodynamic-based gene delivery. 1 --4 Although the mechanism of hydrodynamic-based in vivo gene expression is not clearly understood, it has been suggested that the rapid injection of a large volume of plasmid DNA solution causes shearing forces on the hepatocytes. These forces induce transient pore formation in the plasma membrane, facilitating the direct entry of the plasmid DNA into the cytosol of the hepatocytes, resulting in a high level of transient in vivo gene expression. 1,2,5 --7 Since the discovery of this hydrodynamic gene delivery technique in the 1990s, it has been reported as an effective method of gene delivery in experimental animal models. The introduction of exogenous genes by the hydrodynamic method using plasmid DNA has many advantages such as ease of preparation of large quantities of DNA in a short period of time and stability. Recently, several studies have shown the hydrodynamic-based in vivo expression of several protein molecules (CTLA4-Ig, IL22-Ig, IL10-Ig, CD40-Ig, fetal liver kinase-1, DNA cancer vaccine and hFlex-TRAIL) and their role in various disease conditions such as experimental autoimmune myocarditis, allergic encephalomyelitis, systemic lupus erythematosus, collageninduced arthritis, nephritis and cancer. 8 --17 In this report, we have investigated whether hydrodynamicbased delivery of FcgR genes results in a functional product that can block immune-complex (IC)-mediated inflammation. The receptors (FcgR) for the Fc domain of IgG molecules play a vital role in IC-mediated autoimmune diseases. Inflammatory cells, such as neutrophils, monocytes, and NK cells, express three types of FcgR. 18 --22 FcgRI (CD64) is a high-affinity receptor for monomeric IgG whereas FcgRII (CD32) and FcgRIII (CD16) are low-affinity receptors for monomeric IgG; however, all three bind stably to ICs. Both in vivo and in vitro studies from various laboratories have shown that interaction of FcgRs expressed on inflammatory cells with antibody-coated target cells/tissues is a key event in the destruction of antibody-coated tissues through antibody-dependent cellular cytotoxicity and phagocytosis, 23 --31 which leads to the development of various autoimmune diseases. 28,32 --37 During the development of autoimmune diseases such as arthritis, systemic lupus erythematosus and autoimmune vasculitis, autoantibodies bind to the antigen expressed on cells and form ICs. These ICs bind to inflammatory cells through FcgRs, leading to chronic inflammation and destruction of the target cells. Therefore, blocking the interaction of pathogenic ICs with the cell surface FcgRs expressed on inflammatory cells using recombinant FcgR-Igs could be a potential therapeutic approach. We have previously demonstrated that the administration of a purified dimeric form of a low-affinity FcgR (CD16A-Ig) can be successfully employed to treat IC-mediated acute inflammation in mice. 38 In this report, we have hydrodynamically expressed human low-affinity FcgR-Igs in vivo and studied their effectiveness in blocking IC-mediated inflammation in a murine model. We show that in vivo expressed recombinant FcgR-Ig molecules are secreted in high concentrations and are sustained for longer periods of time in circulation compared with the administered purified FcgR-Ig. These molecules are also as effective as purified FcgR-Igs in blocking the interaction of ICs with inflammatory cells, thus preventing inflammation in vivo for a relatively longer period of time.
RESULTS
Purified human FccR-Igs block IC binding to mouse FccRs in vitro and antibody-mediated inflammation in vivo in mice Previously, we have shown that the purified human CD16A-Ig molecule, when administered in mice, is capable of blocking IC-induced inflammation in a reverse passive Arthus (RPA) model. 38 In this study we have made additional human FcgR-Ig molecules. Before testing the anti-inflammatory effect of human FcgR-Ig molecules in mice, we assessed the ability of purified human FcgR-Ig molecules (CD16A V -Ig, CD16A F -Ig, CD32A R -Ig and CD32A H -Ig) to compete and cross-block IC binding to mouse FcgRs in vitro. We carried out a soluble IC-binding assay using the mouse macrophage cell line (P388D1) as described earlier. 38 P388D1 cells express all four types of mouse FcgRs: CD16A, CD32B, CD64 and FcgRIV. As shown in Figure 1a , all of the hFcgR-Ig molecules, except hCD32A R -Ig, inhibited soluble IC binding to mouse FcgRs expressed on P388D1 cells in a dose-dependent fashion. More than 70% inhibition was achieved when P388D1 cells were co-incubated with 25 mg ml --1 of hCD16A F -Ig, hCD16A V -Ig and hCD32A H -Ig, whereas, hCD32A R -Ig was not able to compete with mouse FcgRs at the same concentration. The results with purified hCD16A F -Ig and hCD32A R -Ig are consistent with our previous studies. 38 The in vivo efficacy of purified human FcgR-Ig molecules was analyzed using RPA, an acute antibody-mediated inflammation in a murine model. 38 In this model, inflammation is initiated by the formation of antigen--antibody complexes at the antibody-injected site. To induce inflammation, rabbit anti-chicken ovalbumin (anti-Ova) IgG was injected intradermally on the dorsal side of the mouse skin, and chicken Ova along with 1% Evan's blue (blue dye) were injected intravenously. Extravasation of inflammatory cells and vascular permeability during the inflammation at the antibodyinjected site can be visualized upon leakage of the blue dye. 38, 39 Before the induction of RPA, hFcgR-Ig molecules (50 mg ml --1 of mouse blood) were administered intravenously into a separate group of mice (n ¼ 3) to study the effect of purified hFcgR-Ig molecules. As shown in Figure 1b , hCD16A F -Ig, hCD16A V -Ig and hCD32A H -Ig inhibited 470% inflammation as measured by the intensity of the Evan's blue extravasation ( Figure 1c ); whereas under similar conditions, hCD32A R -Ig did not inhibit inflammation ( Figure 1b ). The lack of inhibition by purified hCD32A R -Ig may be because of the difference in affinity of human FcgR-Igs toward rabbit IgG binding or because hCD32A R -Ig might have partially denatured during the purification process. As specificity controls, mice treated with 2.4G2 antibody, a monoclonal antibody (mAb) to mouse FcgRs (CD16/32), did not cause RPA ( Figure 1b ).
In vivo expression of human FccR-Ig molecules in mice by the hydrodynamic-based method has a longer half-life Next, we determined the level and kinetics of expression of human FcgR-Ig molecules in vivo. As shown in Figure 2 , all of the hydrodynamically expressed hFcgR-Ig molecules in mice reached maximum expression by 24 h. The concentration of hFcgR-Ig in circulation was found to be B130 mg ml --1 of blood. The in vivo half-life was 9 days for hCD16A F -Ig, whereas for the hCD32A-Ig molecules, the half-life was estimated to be 16 days. hCD16A F -Ig was detected up to 17 days in circulation, whereas hCD32A-Ig molecules were detected until day 24. We reported previously that the in vivo half-life of the hFcgR-Ig molecules is 5 days when administered as purified molecules. 38 These results suggest that the in vivo expression of a foreign gene in mice by the hydrodynamic-based method increases the in vivo half-life of the foreign protein when compared with administration of purified proteins. At present, the reason for increased half-life of hydrodynamically expressed FcgR-Igs is not clear. However, it is possible that the purification process may have made the molecules more susceptible to in vivo degradation.
Hydrodynamically expressed human FccR-Ig molecules block antibody-mediated inflammation in mice
We then determined whether hydrodynamically expressed hFcgR-Ig can block antibody-mediated inflammation in a murine RPA model. In these experiments, a group of mice (n ¼ 12 for each molecule) were injected with plasmid DNA of hFcgR-Ig as described under Materials and Methods. DNA was injected on day 0 and at different time intervals, and a group of mice (n ¼ 3) were used to conduct the RPA for each molecule. We have chosen different time points for each molecule to conduct the RPA as the hydrodynamically expressed hCD16A-Ig and hCD32A-Ig molecules differ in their in vivo half-life. For hCD16A F -Ig, the RPA was carried out on days 1, 3, 7 and 13. As shown in Figure 3a , the in vivo expressed hCD16A F -Ig was able to significantly (P ¼ 0.001) reduce antibody-mediated inflammation up to 3 days. As measured by the intensity of the Evan's blue extravasation, hCD16A F -Ig was able to block inflammation by 83 and 77% on days 1 and 3, respectively, whereas on day 7 it was only able to block 20% (Figure 3a ; left panel). These results suggest that in vivo expressed hCD16A F -Ig can block antibody-mediated inflammation up to 3 days and becomes ineffective by day 7 (Figure 3a ; right panel bar graph). For hCD32A R -Ig and hCD32A H -Ig DNA-injected animals, the RPA was conducted on days 1, 3, 9 and 16. Interestingly, as shown in Figure 3b , the in vivo expressed hCD32A R -Ig was able to block antibody-mediated inflammation completely on day 1, but the blocking efficiency as measured by the intensity of the blue dye began to decline by day 3 and was completely ineffective by day 9 (Figure 3b ; right panel). Most notably, hydrodynamically expressed hCD32A R -Ig blocks IC-mediated inflammation in mice, whereas the purified molecule cannot (compare Figures 1 and 3 ). The in vivo expressed hCD32A H -Ig was able to block antibodymediated inflammation completely up to 9 days ( Figure 3c ). Approximately 50% of RPA was blocked by hCD32A H -Ig even on day 9 and became ineffective on day 16 as indicated by the decrease in the intensity of the blue dye ( Figure 3c ; right panel). As a specificity control, mice were treated with 2.4G2 mAb, which completely blocked RPA on day 3. The untreated group of mice (n ¼ 3) injected with rabbit anti-Ova antibody alone served as the positive control. These results suggest that hydrodynamically expressed hFcgR-Ig molecules are capable of competing with mFcgRs and can effectively block IC binding.
Functionality of hydrodynamically expressed hFccR-Ig molecules
To determine whether the level of expression correlates with the ability to block RPA, plasma was collected from the mice used for RPA experiments before induction of RPA, and the concentration of human FcgR-Igs in the blood of the mice was determined using a sandwich enzyme-linked immunosorbent assay (ELISA). As shown in Figure 4 (upper panel), hCD16A F -Ig was expressed at B120 mg ml --1 of blood up to day 3. Approximately 50% of the hCD16A F -Ig was cleared from circulation by day 7 and was not detectable in circulation on day 13. hCD32A R -Ig and hCD32A H -Ig were expressed at 160 and 120 mg ml --1 of blood, respectively, within 24 h of hydrodynamic injection ( Figure 4 , middle and lower panels). The same concentration was maintained until day 9, and B50% was cleared from circulation by day 16. Although the concentration of FcgR-Ig molecules present within the mice should be sufficient to block RPA, CD16A F -Ig and CD32A R -Ig were not able to block RPA after 3 and 9 days of expression, respectively. This suggests that the level expression of hFcgR-Ig does not correlate with the ability to block RPA when the molecules are in circulation for more than 3 days. Therefore, we determined whether the hFcgR-Ig molecules present in circulation are capable of binding IgG in in vitro assays.
ELISA plates were coated with 10 mg ml --1 of rabbit IgG, and then 100 ml of 1:100 diluted plasma was added to the wells. The plates were washed, and the bound hFcgR-Ig was detected using horseradish peroxidase (HRP)-conjugated anti-human Fc-specific antibody. The mAb-coated wells (CLB-Fcgran-1 for human CD16A and IV.3 for CD32A) and the plasma from naive mice served as specificity controls. As shown in Figure 5 (upper panel), in vivo expressed hCD16A F -Ig bound to rabbit IgG efficiently on day 1 of its expression. On day 3, its binding efficiency to rabbit IgG was reduced by 50% and by day 7 it was no longer able to bind to rabbit IgG. The in vivo expressed hCD32A R -Ig ( Figure 5 , middle panel) bound to rabbit IgG poorly on day 1 of expression, and its binding efficiency was reduced by 50% on day 3. On day 9, it was not able to bind to rabbit IgG. The in vivo expressed hCD32A H -Ig ( Figure 5 , lower panel) bound efficiently to rabbit IgG on day 1 and retained up to 50% of its binding efficiency until day 16. Correlation of the level of expression ( Figure 4 ) and functional activity ( Figure 5 and 3) shows that hCD32A H -Ig and hCD16A F -Ig bind more efficiently to rabbit IgG when compared with hCD32A R -Ig. These data suggest that dimeric FcgR-Ig molecules may become inactive or degraded partially after being present in circulation for several days, and the lack of functionality may vary from molecule to molecule. At present, the reason for the ineffectiveness of CD16A F -Ig and CD32A R -Ig after being in circulation for a few days is not clear.
Hydrodynamically expressed hFccR-Ig molecules are secreted as a homodimer To determine the molecular nature and kinetics of degradation of circulating hFcgR-Ig, we analyzed the plasma by western blot. Previously, we have reported that recombinant hFcgR-Igs secreted by CHO-K1 cell transfectants are disulfide-linked homodimers. 38, 40, 41 As shown in Figure 6a , on day 1, hCD16A F -Ig is secreted as a disulfide-linked homodimer as evidenced by the presence of 120 kDa band under nonreducing conditions and the 70 kDa band under reducing conditions. However, we also observed a band at B200 kDa in CD16A-Ig blots, whereas on day 3 this band had mostly disappeared. The reason for the secretion of this high-molecular-weight band is not clear; however, it may be because of the aggregation of hCD16A F -Ig. We did not observe this high-molecular-weight band when we purified the hCD16A F -Ig molecule in vitro. 40 On day 3, the molecules began to degrade, as suggested by the appearance of low-molecular-weight bands, and was completely degraded by day 13. These results are consistent with the detectable rabbit IgG-binding activity ( Figure 5 ). The hCD32A R -Ig (Figure 6b ) and hCD32A H -Ig (Figure 6c ) molecules are also secreted as disulfidelinked homodimers as seen by the 110 kDa band under nonreducing conditions and a 60 kDa band under reducing conditions. The intensity of the bands under reducing conditions was lower, which may be because of the decreased reactivity of the antibodies with denatured molecules. Interestingly, hCD32A-Ig molecules are more stable in vivo than hCD16A-Ig (compare In addition to the major bands, we observed minor low-molecularweight bands, which may be because of different glycosylation or degradation products of the hCD32A-Ig molecules. These results suggest that the progressive loss of ability to block inflammation in RPA with time by the in vivo expressed FcgR-Ig molecules correlates with the in vitro rabbit IgG-binding activity and is partly because of the degradation of the molecules in circulation.
Hepatocytes and antigen-presenting cells (APCs) such as macrophages in the spleen are responsible for the hydrodynamic expression of hFccR-Ig To investigate the specific organ and cell type involved in the high expression of hFcgR-Ig molecules, a group of mice (n ¼ 3) were hydrodynamically injected with hCD32A H -Ig plasmid DNA. Various organs were then harvested at different time points post DNA injection and subjected to immunohistochemistry. The expression of hCD32A H -Ig was detected using the F(ab)'2 fragment of goat anti-human Fc-specific antibody conjugated with Cy-5. Consistent with previous reports, 1, 42 our results show that hepatocytes are the major cell type responsible for the expression of hFcgR-Igs and maintained expression for up to 48 h after plasmid DNA administration (Figure 7a ). Interestingly, APCs such as macrophages in the red pulp region of the spleen also expressed the hCD32A H -Ig molecules, but not the B-or T-cell zones in the white pulp region (Figure 7b ). Maximum expression was reached after 24 h and declined thereafter (Figure 7b ). In contrast, expression of hCD32A H -Ig was not found in other organs tested such as kidney, lung or heart (figure not shown). These results suggest that in addition to hepatocytes in the liver, APCs such as macrophages present in the red pulp area of the spleen are also responsible for the expression of hFcgR-Ig molecules following the hydrodynamic delivery of plasmid DNA.
DISCUSSION
In the recent past, the significance of low-affinity FcgRs in autoimmune/inflammatory disease conditions has been welldocumented. 43 --47 The interaction of ICs with FcgRs on inflammatory cells is a key event in the progression of IC-mediated diseases. Previously, we have shown that inflammation caused by the interaction of ICs with inflammatory cells can be blocked by administering purified FcgR-Ig molecules. 38, 48, 49 In this report, we Figure 3 ), blood was collected (5 ml) and diluted in 500 ml of PBS/EDTA and plasma was used to detect the expression of human FcgR-Ig molecules by sandwich ELISA as described in Figure 3 . Experiments are an average of three individual mice. Figure 3 was used to determine whether the in vivo expressed hFcgR-Igs bind to rabbit IgG using a sandwich ELISA. Rabbit IgG (100 ml of 10 mg ml --1 ) was coated on ELISA plates overnight, and the binding of hFcgR-Ig molecules to rabbit IgG was determined as described under Materials and Methods. The hFcgR-Ig alleles that bound to BSA-coated wells were taken as nonspecific binding. Experiments are an average of three individual mice. Data are mean±s.d. of triplicates.
demonstrate that the hydrodynamic administration of plasmid DNAs encoding human low-affinity FcgR-Igs is capable of blocking IC-mediated inflammation in a murine RPA model. The hFcgR-Ig molecules were secreted in high concentrations in circulation and sustained for longer periods of time after hydrodynamic administration when compared with the administered purified molecules. Recently, we have reported that the purified hCD32A R -Ig molecules, despite being active in vitro, 41 failed to block inflammation induced by RPA in mice. 38 The reason for the ineffectiveness of the purified hCD32A R -Ig molecule in vivo is not clear. However, it is possible that the purified molecules may not be able to compete with mouse FcgRs for IC binding 38 or may have partially denatured during the purification process, thus leading to its ineffectiveness. Interestingly, in this report we observed that hydrodynamically expressed hCD32A R -Ig molecules are effective in blocking antibody-induced inflammation in mice, suggesting that the hCD32A R -Ig molecules may have been partially denatured during the purification process. These results also suggest that in vivo expressed molecules are more active when compared with purified molecules, indicating that the in vivo expression of a transgene by the hydrodynamic-based method is a more desirable method to study the function of a To determine the specific organ and cell type involved in the expression of hFccR-Ig molecules, a group of mice (n ¼ 3) were hydrodynamically injected with hCD32A H -Ig plasmid DNA (10 mg) and then various organs at different time points were collected and immunohistochemistry was carried out as described under Materials and Methods. (a) Liver sections were stained with a liver mitochondrial marker-specific rabbit antibody to detect hepatocytes followed by FITC-conjugated goat anti-rabbit as secondary antibody (green). Liver sections are also counterstained with Cy-5-conjugated goat anti-human Fcspecific antibody to detect the presence of hCD32A H -Ig expression (red). The merger of green and red colors (yellow) represents the expression of hCD32A H -Ig by hepatocytes. Photographs were taken at Â 40 magnification. (b) Spleen sections were stained with FITC-conjugated macrophage-specific rat antibody to detect macrophages in the spleen (green) and counterstained with Cy-5-conjugated goat anti-human Fc-specific antibody to detect the presence of hCD32A H -Ig expression (red). The yellow color, which is a result of merger of green and red colors, indicates the expression of hCD32A H -Ig by macrophages. Photographs were taken at Â 20 magnification. WRP represents white pulp region where T and B cells are present. RPR represents red pulp region around WRP where the hCD32A H -Ig molecules were expressed by macrophages. particular gene product in vivo. It has been shown that after hydrodynamic injection of plasmid DNA, a high expression of recombinant luciferase was found in the liver, whereas a very low level of expression was observed in the spleen, kidney, lung and heart. 1 In agreement with this, we observed that the hepatocytes are the major cell types responsible for the high level of expression of recombinant molecules. Interestingly, we also found that APCs present in the red pulp region of the spleen are also responsible for the expression of recombinant molecules and not T or B cells present in the white pulp region (Figure 7) . In contrast, we did not observe the expression of recombinant molecules in the other organs tested such as kidney, lung and heart (data not shown). Taken together, these results suggest that the hepatocytes in the liver and APCs in the spleen are responsible for the expression of recombinant molecules when plasmid DNA is hydrodynamically injected in mice.
Recently, hydrodynamic-based in vivo expression of several Ig fusion protein molecules such as interleukins and cell adhesion molecules (CTLA4-Ig, IL22-Ig, IL10-Ig and Flex/TRIAl-Ig) were studied, and their role in various disease conditions was established. 8 --10,15 --17 For instance, hydrodynamically expressed CTLA4-Ig dramatically reduced experimental autoimmune myocarditis by blocking the costimulatory signal from the T cells. The in vivo expression of CTLA4-Ig was B2 mg ml --1 of blood and was detectable up to 16 days. 10 In this report, for the first time, we have expressed hFcgR-Ig molecules by injecting naked plasmid DNA in mice and showed that hydrodynamically expressed hFcgR-Ig molecules have a longer half-life compared with the purified molecules, remain as dimers in circulation and are effective in blocking IC-mediated inflammation in a mouse model for an extended period of time. It has been shown that the in vivo half-life of purified monomeric hCD32A was only 30 min in mice, 25 whereas recently we have shown that the in vivo half-life of purified, dimeric forms of Fc fusion hCD16A F -Ig and hCD32A R -Ig was 120 h when administered intravenously to mice. 38 In this report we observed that the hydrodynamically expressed FcgR-Ig molecules exhibited a longer half-life when compared with purified FcgR-Ig molecules. The reason for this prolonged halflife is not clear; however, this may be because of continuous production of the FcgR-Ig molecules from hepatocytes and macrophages present in the spleen, which took up the DNA during hydrodynamic injection. Moreover, it has been shown that the in vivo half-life of Fc fusion proteins is because of the presence of the Fc domain. The Fc domain binds to neonatal Fc receptors (FcRn) and protects the IgG from degradation by the endocytic machinery of cells. 50 The Fc domain used in the present investigation is mutated to abolish the FcgR-binding activity. 51 --53 As both FcgRs and FcRn bind to different sites of the Fc domain, 54, 55 the mutation that we introduced in the Fc domain of the FcgR-Ig molecules will not affect the FcRn-binding activity, therefore potentially aiding in extending the in vivo half-life of hFcgR-Ig molecules. It has been shown that hydrodynamically injected plasmid DNA can stay in the hepatocytes for up to 3 days after administration. 15, 42 Alternatively, hydrodynamically expressed FcgR-Igs may be in a less denatured state in circulation because of lack of exposure to harsh acidic conditions that are used for affinity purification of FcgR-Igs.
In conclusion, we have demonstrated that the hydrodynamic delivery of plasmid DNA encoding hFcgR-Igs inhibited antibodymediated inflammation in mice. The hFcgR-Ig molecules are expressed at high levels, are intact and dimeric in nature and sustained in circulation for an extended period of time. The data presented herein will be useful in studying the consequences of uncoupling IC binding to FcgRs expressed on inflammatory cells during IC-mediated inflammatory/autoimmune diseases such as arthritis, systemic lupus erythematosus and autoimmune vasculitis. This approach also obviates the laborious purification process of recombinant molecules to delineate the specific role of a particular gene of interest in vivo within a short period of time and suggests that FcgR-Ig molecules can be expressed in vivo. Furthermore, these hydrodynamically expressed molecules are useful in evaluating the roles and therapeutic use of FcgRs during the course of various inflammatory and autoimmune diseases.
MATERIALS AND METHODS Reagents
The HRP-conjugated anti-human Fc antibody and OVA were purchased from Sigma (St Louis, MO, USA). The Ovalbumin-fluorescein isothiocyanate (FITC), rabbit anti-Ovalbumin IgG and rabbit IgG were from Roche Molecular Biochemicals (Indianapolis, IN, USA) . HRP-substrate and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels were from Bio-Rad (Hercules, CA, USA). DNA preparation kits were from QIAGEN (Valencia, CA, USA). DH5a bacteria, CHO serum free media and lipofectamin were from Invitrogen (Carlsbad, CA, USA). The Micro BCAprotein assay kit was from Pierce (Rockford, IL, USA). Quick-change II sitedirected mutagenesis kit was from Stratagene (La Jolla, CA, USA). Cell culture reagents were from Life Technologies (Gaithersburg, MD, USA). 2.4G2 (anti-mouse mAb CD16/32) mAb was from BD Biosciences (San Jose, CA, USA). Anti-human CD16 and CD32A mAb were referenced previously. 40, 41 Human Fc-specific Cy5-conjugated F(ab)'2 fragment of goat antibody was from Jackson Immunoresearch Laboratories (West groove, PA, USA). Mouse macrophage-specific FITC-conjugated rat monoclonal (clone no. BM8) antibody F4/80, rabbit polyclonal mouse liver mitochondrial marker antibody (CSP1) and FITC-conjugated, affinitypurified goat polyclonal antibody against rabbit IgG were purchased from Abcam (San Francisco, CA, USA). C57BL/6 (8 --10 weeks old) female mice were from Jackson laboratory (Bar Harbor, ME, USA). The animal experiments were conducted according to the Emory University institutional animal care and use committee protocol.
Construction of human FccR-Ig plasmids
The construction of the dimeric form of hCD32A R -Ig and hCD16A F -Ig was carried out by ligating the extracellular domain of hCD32A R or CD16A F to the mutated Fc domain of the human IgG1 heavy chain as described earlier. 38, 40, 41 The mutations in the Fc domain were shown to abolish the binding of FcgRs. 51 --53 The hCD32A H -Ig and hCD16A V -Ig alleles were constructed by Quick-change II site-directed mutagenesis kit using hCD32A R -Ig and hCD16A F -Ig DNA as a template. Complementary DNAs (cDNAs) encoding the FcgR-Ig were then subcloned into the pcDNA3.1 expression vector with neomycin selection marker. 40, 41 The plasmid DNAs of hFcgR-Ig were transfected into CHO-K1 cells and culture supernatant was collected and used to purify the FcgR-Ig molecules using a Protein-G column as previously described. 40, 41 Soluble IC-binding assay Soluble IC was prepared as described. 38, 41 Briefly FITC-Ova was mixed with rabbit anti-Ova IgG (1:1 molar ratio) and incubated for 4 h at 4 1C. The complex was centrifuged using a microcentrifuge at 15 000 r.p.m. for 30 min at 4 1C and the supernatant was used for the FITC-IC-binding assay. The P388D1 mouse macrophage cells (50 ml of 5 Â 10 6 ) were preincubated with recombinant receptors or mAbs for 30 min at 4 1C and then incubated with FITC-IC (20 mg ml --1 ) in binding buffer (phosphate-buffered saline (PBS)/EDTA with 1% bovine serum albumin (BSA), pH 7.4) for 1 h at 4 1C. The cells were then washed and analyzed by flow cytometry.
Hydrodynamic-based injection of FccR-Ig in mice
Hydrodynamic-based injection of plasmid DNA was carried out as described. 1, 56 Briefly, 10 mg of pcDNA3.1 plasmid vector containing human FcgR-Ig cDNAs (hCD16A F -Ig, hCD16A V -Ig, hCD32A R -Ig or hCD32A H -Ig) was diluted in 1.6 ml of sterile saline (0.9% NaCl) and injected into each group of mice (n ¼ 5 per group) through the tail vein within 5 --7 s, using a 27.5-gauge needle. Subsequently, 5 ml blood samples were collected at several time points and diluted to 500 ml in PBS/5 mM EDTA, and the plasma was separated by centrifugation. The plasma samples were frozen immediately at À80 1C for future analysis.
Estimation of human FccR-Ig levels in mice blood
Plasma collected at different time points was used to detect FcgR-Ig dimers by sandwich ELISA as described. 38 Briefly, ELISA plates were coated with 100 ml of 10 mg ml --1 anti-hCD16A (CLBFcgran-1) and anti-hCD32A (IV.3) mAbs overnight at 4 1C. The wells were then blocked with PBS/5 mM EDTA/ 1% BSA. After washing, 100 ml of the plasma samples were added into the wells and incubated for 1 h. The wells were washed and then incubated for another 1 h after adding 100 ml of HRP-conjugated goat anti-human IgG Fc-specific antibody. HRP substrate was added to the washed wells and read at 450 nm. The plasma from mice injected with PBS served as a specificity control. To quantify the level of FcgR-Ig dimers in the blood, purified hCD16A F -Ig and hCD32A R -Ig were used as standards, whereas BSA-coated wells served as negative controls.
RPA reaction
RPA was carried out as described. 38 Briefly, the mice (n ¼ 12) were hydrodynamically injected with 10 mg of human FcgR-Ig plasmids in 1.6 ml of saline. Then, RPA was carried out at different time points. For each time point, a group of mice (n ¼ 3) was used. Before the initiation of RPA, blood was collected (5 ml), diluted to 500 ml with PBS/EDTA and centrifuged to collect plasma. The diluted plasma was used to analyze the hFcgR-Ig molecules in the circulation. At each time point, a group of mice (n ¼ 3) was injected with 12.5 or 25 mg per site of anti-Ova intradermally in a total volume of 25 ml of PBS at different sites. After 5 min following the injection of anti-Ova antibody, RPA was initiated by injecting 100 ml PBS containing 500 mg of ovalbumin and 1% Evan's blue through the tail vein. A group of mice (n ¼ 3) injected with PBS served as a control at each time point. Both the control and experimental mice were euthanized after 3 h and the injection sites on the reverse side of the skin were examined for extravasation of the blue dye. Photographs were taken immediately and used to quantitate the degree of inflammation elicited by RPA reaction. The intensity of each dermal lesion, seen blue in the photographs, was quantified using ImageJ (National Institute of Health, Bethesda, MD, USA) and KaleidaGraph (Synergy Software, Reading, PA, USA).
Western blot analysis
The plasma samples collected at various time points after the hydrodynamic injection of FcgR-Ig plasmid DNA were subjected to western blot analysis. Briefly, 20 ml of plasma was mixed with SDS-PAGE sample buffer of both reducing and nonreducing conditions. Samples were boiled for 5 min and subjected to SDS-PAGE under reducing or nonreducing conditions. After blotting the protein onto a polyvinylidene fluoride membrane, the proteins were detected using a HRP-conjugated goat anti-human Fc-specific antibody.
Analyses of ligand-binding ability of circulating FccR-Ig by ELISA
The plasma sample collected at various time points were used to detect the ligand-binding activity of hydrodynamically expressed human FcgR-Igs. Briefly, ELISA plates were coated overnight with rabbit IgG (100 ml of 10 mg ml --1 ) and blocked for 1 h with a binding buffer. The plasma samples from mice injected with human FcgR-Ig (100 ml of 1:100 diluted) were then added to the plates, and the incubation continued for 1 h at 4 1C. The FcgR-Ig bound to the rabbit IgG was detected as described in a previous section. The hFcgR-Igs bound to BSA-coated wells were taken as nonspecific binding. Experiments are representative of three individual experiments. Data are mean ± s.d. of triplicates.
Immunohistochemistry
Expression of FcgRs-Ig molecules in different organs was determined by immunohistochemistry. Briefly, 10 mg of pcDNA3.1 plasmid vector containing human hCD32A H -Ig was injected hydrodynamically into a group of mice (n ¼ 3 per group) as described above. Subsequently, different organs (liver, spleen, kidney, lung and heart) were collected at several time points and snap frozen immediately using liquid nitrogen. Cryosections (5 mm) were taken and stained for the hCD32A H -Ig, hepatocytes and macrophages using antibodies. The specific antibodies are: F4/80, a mouse macrophagespecific FITC-conjugated rat monoclonal antibody; CSP1, rabbit polyclonal mouse liver mitochondrial marker antibody; and a Cy5-conjugated F(ab)'2 fragment of goat antibody specific to human Fc domain.
Statistical analysis
A statistical comparison of the control and treated samples was performed using Student's t-test, with Po0.01 (*) considered as significant and Po0.001 (**) considered as highly significant.
